HISOAR(SZ:002099) Ge Long Hui A P P·2025-12-09 08:31Core Viewpoint - The collaboration between Haisheng Pharmaceutical and Hangzhou Advanced Research Institute aims to establish an Advanced Synthesis Technology Industry Research Institute, focusing on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials, with a total investment of 50 million RMB [1][2]. Group 1 - The partnership is based on principles of complementary advantages, market leadership, openness, fairness, and mutual benefit, leveraging both parties' talent, technology, and resource advantages [1]. - The research direction will emphasize green drug synthesis methods and precise modification of active molecules, contributing to sustainable and efficient synthesis in the pharmaceutical sector [1]. - The collaboration is expected to enhance the company's product variety and reserve, reduce costs, and improve product competitiveness while exploring innovative drugs and biopharmaceuticals [2]. Group 2 - The research team from Hangzhou Advanced Research Institute has published significant academic papers in prestigious journals, supporting the development of safe and economical synthesis methods that could revolutionize traditional high-risk processes [1]. - The agreement aims to cultivate high-quality, skilled application-oriented talents to address challenges in research and production, ultimately improving economic efficiency [2]. - The initiative will also explore the integration of artificial intelligence technology in chemical synthesis, optimizing the company's business structure and promoting long-term strategic planning for sustainable development [2].